Bayer not interested in buying Actelion -sources

FRANKFURT, Oct 8 (Reuters) - German drugmaker Bayer BAYGn.DE is not interested in taking over smaller Swiss peer Actelion ATLN.VX, three sources close to Bayer said, rejecting speculation voiced by some analysts.

A Bayer spokesman declined to comment on the matter.

Shares in Actelion surged as much as 12 percent on Friday, building on the previous day’s gains, with traders citing further talk that Europe’s largest biotech could be an acquisition target.

Kepler Capital Markets analyst Tero Weckroth had said in a note he believes Bayer would have the best reasons for acquiring Actelion.

Both Bayer and Actelion have products to treat high blood pressure in the lungs.

Reporting by Ludwig Burger and Philipp Halstrick